{"id":167470,"date":"2025-03-19T08:50:06","date_gmt":"2025-03-19T12:50:06","guid":{"rendered":"https:\/\/44.250.171.167\/?p=167470"},"modified":"2025-03-19T08:50:06","modified_gmt":"2025-03-19T12:50:06","slug":"sanofi-india-ltd-q3fy25-34-fall-in-profits","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/sanofi-india-ltd-q3fy25-34-fall-in-profits\/","title":{"rendered":"Sanofi India Ltd Q3FY25; 34% fall in Profits"},"content":{"rendered":"<p>Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.<\/p>\n<h2>\nFinancial Results:<\/h2>\n<p>Sanofi India Ltd reported Revenues for Q3FY25 of \u20b9515.00 Crores up from \u20b9469.00 Crore year on year, a rise of 9.81%.<\/p>\n<p>Total Expenses for Q3FY25 of \u20b9407.00 Crores up from \u20b9379.00 Crores year on year, a rise of 7.39%.<\/p>\n<p>Consolidated Net Profit of \u20b991.00 Crores down 34.06% from \u20b9138.00 Crores in the same quarter of the previous year.<\/p>\n<p>The Earnings per Share is \u20b939.70, down 33.69% from \u20b959.87 in the same quarter of the previous year.<\/p>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-large wp-image-167471\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/4-9-839x1024.png\" alt=\"\" width=\"640\" height=\"781\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/4-9-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/4-9-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/4-9-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/4-9-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/4-9.png 1489w\" sizes=\"auto, (max-width: 640px) 100vw, 640px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines. Financial Results: Sanofi India Ltd reported Revenues for Q3FY25 of \u20b9515.00 Crores up from \u20b9469.00 Crore year on year, a rise [&hellip;]<\/p>\n","protected":false},"author":1863,"featured_media":167471,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392,5747],"tags":[11776,11978,10162],"class_list":["post-167470","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","category-healthcare-stocks","tag-active-pharmaceutical-ingredients","tag-medicines","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/4-9.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":165923,"url":"https:\/\/alphastreet.com\/india\/sanofi-india-ltd-q2fy25-46-fall-in-profits\/","url_meta":{"origin":167470,"position":0},"title":"Sanofi India Ltd Q2FY25; 46% fall in Profits","author":"Chirag Gupta","date":"December 5, 2024","format":false,"excerpt":"Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines. Financial Results: Sanofi India Ltd reported Revenues for Q2FY25 of \u20b9524.00 Crores up from \u20b9491.00 Crore\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/download-7.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/download-7.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/download-7.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/download-7.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/download-7.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/download-7.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":167751,"url":"https:\/\/alphastreet.com\/india\/glaxosmithkline-pharmaceuticals-ltd-q3fy25-400-rise-in-profits\/","url_meta":{"origin":167470,"position":1},"title":"Glaxosmithkline Pharmaceuticals Ltd Q3FY25; 400% rise in Profits","author":"Divyansh_Kasana","date":"April 4, 2025","format":false,"excerpt":"GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site) Financial Results: Glaxosmithkline Pharmaceuticals Ltd reported Revenues for Q3FY25 of \u20b9949.00 Crores up from \u20b9805.00 Crore year on year, a rise of 17.89%. Total Expenses for Q3FY25 of \u20b9677.00 Crores\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/04\/H-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/04\/H-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/04\/H-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/04\/H-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/04\/H-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/04\/H-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":161096,"url":"https:\/\/alphastreet.com\/india\/sanofi-india-ltd-q4fy24-28-fall-in-profits\/","url_meta":{"origin":167470,"position":2},"title":"Sanofi India Ltd Q4FY24; 28% fall in Profits","author":"Chirag Gupta","date":"May 13, 2024","format":false,"excerpt":"Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products. Financial Results: Sanofi India Ltd reported Revenues for Q4FY24 of \u20b9732.00 Crores down from \u20b9736.00 Crore year on year, a fall of 0.54%. Total Expenses for Q4FY24 of \u20b9524.00 Crores up from \u20b9517.00 Crores year on year,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-91.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-91.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-91.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-91.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-91.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-91.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":166723,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-ltd-q3fy25-2-rise-in-profits\/","url_meta":{"origin":167470,"position":3},"title":"Dr Reddys Laboratories Ltd Q3FY25; 2% rise in Profits","author":"Divyansh_Kasana","date":"February 7, 2025","format":false,"excerpt":"Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Financial Results: Dr Reddys Laboratories Ltd reported Revenues for Q3FY25 of \u20b98,381.00 Crores up from \u20b97,237.00 Crore year\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/U-4.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/U-4.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/U-4.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/U-4.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/U-4.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/U-4.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":166509,"url":"https:\/\/alphastreet.com\/india\/torrent-pharmaceuticals-ltd-q3fy25-14-rise-in-profits\/","url_meta":{"origin":167470,"position":4},"title":"Torrent Pharmaceuticals Ltd Q3FY25; 14% rise in Profits","author":"Chirag Gupta","date":"January 24, 2025","format":false,"excerpt":"Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. Financial Results: Torrent Pharmaceuticals Ltd reported Revenues for Q3FY25 of \u20b92,809.00 Crores up from \u20b92,732.00 Crore year on year, a rise of 2.82%. Total Expenses for Q3FY25 of\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/a4015346-c746-4ecb-8769-d2f4c3bc4704.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/a4015346-c746-4ecb-8769-d2f4c3bc4704.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/a4015346-c746-4ecb-8769-d2f4c3bc4704.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/a4015346-c746-4ecb-8769-d2f4c3bc4704.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/a4015346-c746-4ecb-8769-d2f4c3bc4704.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/a4015346-c746-4ecb-8769-d2f4c3bc4704.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":167036,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-ltd-q3fy25-6-rise-in-profits\/","url_meta":{"origin":167470,"position":5},"title":"Alkem Laboratories Ltd Q3FY25; 6% rise in Profits","author":"Divyansh_Kasana","date":"February 24, 2025","format":false,"excerpt":"Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107) Financial Results: Alkem Laboratories Ltd reported Revenues for Q3FY25 of \u20b93,374.00 Crores up from \u20b93,324.00 Crore year on year,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/U-15.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/U-15.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/U-15.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/U-15.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/U-15.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/U-15.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/167470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=167470"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/167470\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/167471"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=167470"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=167470"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=167470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}